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Abstract
Background: Fatigue is a common symptom of chronic hepatitis C virus (HCV) infection and a frequent side-effect
of peginterferon/ribavirin (PR) therapy for HCV. This study evaluated the impact of adding the oral HCV NS3/4A protease
inhibitor simeprevir to PR on patient-reported fatigue and health status among patients with chronic HCV genotype
1 infection enrolled in the Phase IIb PILLAR and ASPIRE trials [NCT00882908; NCT00980330].
Methods: Treatment-naïve patients (PILLAR, n = 386) and treatment-experienced patients (ASPIRE, n = 462) were
randomized to simeprevir plus PR (simeprevir/PR) or placebo plus PR (placebo/PR). In PILLAR, duration of PR
treatment in the simeprevir/PR groups was determined using response-guided therapy (RGT) criteria. PR could
be terminated at Week 24, instead of Week 48, if HCV RNA was <25 IU/mL by Week 4 and then undetectable at
Weeks 12, 16, and 20. In both studies, patients completed the Fatigue Severity Scale (FSS) and EQ-5D quality-of-life
questionnaire in their native language at baseline and throughout the studies up until Week 72.
Results: During the first 24 weeks of treatment, mean FSS total score was increased to a similar degree compared with
baseline among patients receiving simeprevir/PR or placebo/PR in both studies indicating increased fatigue severity.
Mean FSS scores returned to values comparable with baseline among patients receiving simeprevir/PR after Week 24 in
PILLAR (after treatment completion for the majority of patients) and in ASPIRE (after Week 48), consistent with RGT
enabling early termination of all treatment at Week 24 in 82.2% of simeprevir/PR-treated patients in the PILLAR study.
Similar results were observed for EQ-5D, with simeprevir/PR-treated patients experiencing less time with worse health
problems according to EQ-5D scores compared with placebo/PR groups in both studies, and more rapid improvement
in health status associated with shorter treatment duration in the PILLAR study.
Conclusions: Combination of simeprevir with PR did not increase patient-reported fatigue severity or health status
impairments beyond that reported by patients treated with PR alone. Many patients treated with simeprevir/PR
returned to pretreatment fatigue and health status levels sooner due to increased treatment efficacy that enabled
shorter duration of all therapy, compared with PR alone.
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Background
Hepatitis C virus (HCV) is a major public health challenge.
Recent estimates by the World Health Organization sug-
gest that approximately 130–170 million people are chron-
ically infected with HCV worldwide and more than 350000
people are estimated to die from hepatitis C-related liver
disease each year [1]. Chronic HCV infection significantly
impairs health-related quality of life (HRQoL), affect-
ing mental, social, and physical function, as well as
general health [2,3]. Although often characterized as
asymptomatic, 50–70% of individuals with chronic HCV
infection report fatigue [4-6]. Furthermore, Sarkar et al.
argue that treatment for HCV is warranted for patients
without extensive liver damage if they are experiencing sig-
nificant problems due to fatigue [7]. The potential causative
factors of fatigue in HCV are unclear with some evidence
suggesting fatigue results from comorbid depression and
anxiety disorders, while other studies implicate the impact
of HCV on liver fibrosis or neuroinvasion [7-11].
Over the past decade, the standard-of-care treatment for
HCV infection has been a combination of peginterferon-α
and ribavirin (PegIFN-α/RBV [PR]) [12,13]. However,
although sustained virologic response (SVR) rates have
substantially improved with PR for some patients, a
48-week regimen of PR alone delivers suboptimal re-
sponse rates (approximately 40–50%) in patients with
HCV genotype 1 infection [12,14,15]. Furthermore, the
incidence and severity of fatigue increases further dur-
ing treatment with PR, which is attributed to multiple
factors but most often to reductions in hemoglobin as-
sociated with treatment [16-18].
The introduction of direct-acting antiviral therapies
such as NS3/4A protease inhibitors (PIs) in combination
with PR heralds a new and promising advance for the
treatment of HCV infection [19]. In addition to im-
proved SVR rates compared with PR in both treatment-
naïve and treatment-experienced patients with genotype 1
HCV infection, regimens containing a PI with PR allow
clinicians to shorten PR treatment using response-guided
therapy (RGT) [20,21]. With RGT, treatment decisions are
made according to whether patients achieve certain on-
treatment virologic response milestones, thereby enabling
patients to qualify for a shortened duration of PR therapy.
More recently, promising results from two Phase II studies,
PILLAR and ASPIRE, have been reported in treatment-
naïve and treatment-experienced patients with genotype 1
HCV infection treated with triple therapy incorporating the
investigational, once-daily, oral HCV NS3/4A PI, simepre-
vir (TMC435) [22,23].
The aim of the current analysis was to examine the
impact of adding simeprevir to PR therapy on patient-
reported fatigue and health status in patients with
chronic HCV infection enrolled in the PILLAR and
ASPIRE studies, using the Fatigue Severity Scale (FSS)
and the European Quality of Life 5-Dimensions (EQ-5D)
questionnaires.
Methods
Study design
The PILLAR and ASPIRE trials were Phase IIb, multicen-
ter, randomized, double-blind, placebo-controlled studies
evaluating the efficacy and safety of once-daily simeprevir
combined with PR in chronically infected treatment-naïve
(PILLAR) or treatment-experienced (ASPIRE) HCV geno-
type 1 patients. The PILLAR and ASPIRE study designs
are described in detail elsewhere [22,23], therefore only a
brief summary is provided here.
In the PILLAR study treatment-naïve patients were
randomized to one of five treatment regimens compris-
ing simeprevir 75 or 150 mg administered orally once-
daily in combination with PR (simeprevir/PR) or placebo
in combination with PR (placebo/PR) (Figure 1). The
treatment duration for triple therapy was either 12 or
24 weeks, with patients who were randomized to 12 weeks
of triple therapy receiving an additional 12 weeks of PR.
In addition, patients receiving regimens containing sime-
previr were eligible for shortened duration of treatment
using an RGT algorithm. On this basis, patients completed
all therapy at Week 24 of treatment if they achieved HCV
RNA <25 IU/mL at Week 4 and were undetectable at
Weeks 12, 16, and 20. Simeprevir-treated participants
who did not meet these virologic milestones continued
therapy for up to 48 weeks, as did the PR group.
In the ASPIRE study, patients with null response, par-
tial response, or relapse to prior PR received treatment
comprising simeprevir 100 or 150 mg once daily for 12,
24, or 48 weeks plus PR for 48 weeks. In all of the sime-
previr treatment arms, when patients were not receiving
simeprevir, they received a matched placebo. For all pa-
tients, the 48-week treatment period was followed by
post-treatment follow-up for up to 72 weeks after the
start of treatment. No RGT was used in the ASPIRE
study.
In all treatment groups in both studies, patients re-
ceived PegIFN-α-2a administered as a subcutaneous in-
jection (180 μg once weekly) and RBV as oral tablets
(1000 or 1200 mg/day, dependent on body weight). Both
study protocols were reviewed by the appropriate Inde-
pendent Ethics Committee/Institutional Review Board at
each participating study center and the studies were
conducted in accordance with the ethical principles of
the Declaration of Helsinki and in accordance with
Good Clinical Practice guidelines. Between 30 March
and 28 September 2009, 57 Institutional Ethics Commit-
tees in 15 countries approved the protocol for PILLAR.
The protocol for ASPIRE was approved by 54 Institutional
Ethics Committees in 14 countries between 17 September
and 24 December 2009. A list of the investigators and
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Ethics Committees who approved these protocols is pro-
vided in the Additional file 1 for this article. All patients
were required to provide written informed consent prior
to participation in the studies.
In the PILLAR study, the primary endpoint was SVR
at Week 72 (defined as the proportion of participants
with HCV RNA <25 IU/mL and undetectable at Study
Week 72); secondary endpoints included SVR at 12 and
24 weeks post-treatment. In the ASPIRE study the pri-
mary efficacy endpoint was the proportion of patients
with an SVR defined as HCV RNA <25 IU/mL undetect-
able at 24 weeks after the planned end of treatment
(SVR24). Secondary efficacy endpoints included the pro-
portion of patients with a rapid virologic response (RVR;
HCV RNA <25 IU/mL undetectable at Week 4) and
proportion of patients with SVR 12 weeks after the
planned end of treatment (SVR12).
Patient-reported outcomes
Patients independently completed the 9-item FSS ques-
tionnaire [24,25] and EQ-5D at baseline, throughout the
PILLAR and ASPIRE trials (FSS: Weeks 4, 12, 24, 36, 48,
60, and 72; EQ-5D: Weeks 24, 48, and 72) and at the
time of early treatment discontinuation, if applicable.
In common with the EQ-5D, the FSS is not specific
for patients with HCV infection: both have been used
across a wide range of chronic diseases [26-29]. The FSS
has, however, been previously validated in patients with
Figure 1 PILLAR and ASPIRE trial designs.
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chronic hepatitis C [30-32]. In addition, it has been used
to evaluate the experience of fatigue as a symptom of
hepatitis C disease as well as a treatment adverse event
(AE), where lower levels of fatigue were reported post-
treatment in patients with SVR, and worsening fatigue
was associated with treatment discontinuation [33].
Using the FSS questionnaire, patients were asked to
assign a score of between 1 (completely disagree) and 7
(completely agree) to each of the 9 FSS items designed
to rate the extent of fatigue symptoms and their impact
on patient functioning (including motivation, exercise,
physical function, carrying out duties, and interference
with work, family, or social life); a higher score indicated
a higher degree of fatigue. An FSS total score was then
calculated based on the mean of the 9-item scores (range
1–7, higher total score indicates greater fatigue). The
FSS in PILLAR used a 14-day recall period, while FSS
recall in ASPIRE was ‘the past 7 days’.
The EQ-5D is a generic preference-based measure of
HRQoL comprising five questions and a visual analog
scale (VAS) to measure general health status [27,34]. Pa-
tients rated their health states on five health domains:
Mobility, Self Care, Usual Activities, Pain/Discomfort,
and Anxiety/Depression. Domain scores for each dimen-
sion reflect one of three health states (level 1, no prob-
lems; level 2, some problems; level 3, extreme problems).
The five domains were summarized using a descriptive
system and as one single value, the EQ-5D valuation
index (range 0–1). In order to determine the valuation
index, all of the possible 243 unique health states that
could be defined using this system were given a utility
score using an existing tariff. The EQ-5D tariff repre-
sented the general public’s preferences as determined
using time trade-off and differs according to country.
For this study, the UK tariffs were used to assign popula-
tion preference weights to the EQ-5D domains to produce
the EQ-5D valuation index scores analyzed [35]. The
EQ-5D VAS score utilized a score range from 0 to 100,
with a score of 100 representing the best imaginable health
status and a score of 0 the worst imaginable health status.
Both the FSS and EQ-5D questionnaires were only ad-
ministered if a validated translation was available in the
local language and only prior to all other trial-related
procedures planned during the visit. To independently
complete both questionnaires, patients had to be able to
read and write and were not permitted to receive help
from anyone accompanying them (e.g. family members
and friends) or trial staff, in interpreting or responding
to the questions. However, if a patient was unable to
read, or had visual or other physical limitations that
made it difficult to read or complete the questionnaires,
trained trial staff could read the questions and response
options aloud, and record the patient’s responses. Trial-site
staff reviewed completed questionnaires to ensure that all
questions were completed, and if missing items were
noted, patients were asked to complete these items before
any other study procedures were conducted.
Data analysis
The 9-item responses in the FSS were combined into
one total score per time point by calculating the mean of
all non-missing items. If the number of missing items
was 4 or more, the total score was defined as missing.
Descriptive statistics of the actual FSS total scores and
changes from baseline per time point were generated. The
area under the curve (AUC) from baseline to Week 72 be-
tween the simeprevir/PR and the placebo/PR treatment
groups was compared using a piecewise-linear mixed model.
Treatment group and time were included as factors.
The incidence of level scores in each EQ-5D dimension
(Mobility, Self-care, Usual Activities, Pain/Discomfort,
and Anxiety/Depression), actual EQ-5D VAS scores (range
0–100) and EQ-5D index scores (range 0–1) and their
changes from baseline were summarized per time point.
Descriptive statistics of the actual values and the changes
from baseline (for EQ-5D VAS and valuation index) were
generated per time point. The utility decrement associated
with both PR alone and simeprevir/PR therapy was calcu-
lated by comparing the baseline EQ-5D Index score with
the average score captured during the year of treatment
(Weeks 24–48). No statistical comparisons of EQ-5D
scores were conducted as none were pre-specified in the
a priori statistical analysis plan.
For both the FSS and EQ-5D, sensitivity analyses were
performed based on the last-observation-carried-forward
approach (LOCF).
The degree of change in FSS score that is considered
clinically important in patients with HCV infection has
not been reported in prior validation of the FSS [30].
Analyses to establish the amount of change in FSS
scores that was clinically important for patients receiving
treatment for HCV infection are included to help inter-
pret trial results. A blinded analysis of FSS and EQ-5D
data from PILLAR and ASPIRE were linked with spontan-
eous reports of fatigue AEs, encompassing the Medical
Dictionary for Regulatory Activities (MedDRA) preferred
terms ‘fatigue’ and ‘asthenia’, to the FSS scores. For each
patient the first (and worst if more than one) fatigue AE
occurring at any time within a recall period was retained
until a worse AE was recorded during a later recall period.
A case control method was then employed whereby a con-
trol was selected from among patients who did not experi-
ence a fatigue AE during the study by matching with
gender, age and ethnicity. Independent analysis of FSS
scores for both studies at baseline and at the visit at which
the worst fatigue AE was recorded, and change from base-
line FSS scores were compared for cases versus controls
using t-tests.
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Results
Patient characteristics
In total, 386 patients were randomized and treated in the
PILLAR study (simeprevir/PR therapy, n = 309; placebo/
PR, n = 77) and 462 patients were randomized and treated
in the ASPIRE study (simeprevir/PR therapy, n = 396;
placebo/PR, n = 66). Patient demographic and baseline
disease characteristics for both studies are summarized
in Table 1. The majority of patients were Caucasian
and there was a slight predominance of males, particularly
in the ASPIRE study. Median age overall (simeprevir/PR and
placebo/PR groups combined) was 46.5 years (range 18–69)
in the PILLAR study and 50.0 years (range 20–69) in the
ASPIRE study. HCV RNA levels were >800 000 IU/mL in
more than 80% of patients overall in both studies and
over half of the patients had HCV genotype 1b infection
(PILLAR, 54.3%; ASPIRE, 57.6%). Mean baseline FSS,
EQ-5D VAS, and EQ-5D valuation index scores were
comparable between the simeprevir/PR and placebo/PR
treatment groups in both the PILLAR and ASPIRE studies
and were also comparable between studies (Table 1).
Clinical efficacy
Clinical efficacy data from the PILLAR and ASPIRE
studies have been published elsewhere [22,23]. In the
PILLAR study a higher proportion of patients achieved
the primary endpoint of SVR72 (78.6% simeprevir/PR vs
64.9% of placebo/PR patients). Furthermore, among the
simeprevir/PR-treated patients in the PILLAR study,
73.5% achieved RVR and 92.1% of these patients subse-
quently achieved SVR24. In comparison, only 5.2% of
patients in the placebo/PR group achieved RVR. Overall,
82.2% of simeprevir/PR-treated patients completed
treatment by Week 24 according to RGT criteria (HCV
RNA <25 IU/mL at Week 4, then undetectable at
Weeks 12, 16, 20) and 91.3% of these patients subse-
quently achieved SVR24. Similarly, in the ASPIRE study,
a higher proportion of simeprevir/PR-treated patients
compared with placebo/PR-treated patients achieved
SVR24 (primary endpoint, 69.2 vs 22.7%) and RVR
(62.4 vs 1.5%) (Figure 2).
Fatigue as an AE
Fatigue was reported as an AE in 42.4% of all simepre-
vir/PR-treated patients in the PILLAR study (vs 48.1% of
placebo/PR-treated patients) and 22.3% of these patients
had a fatigue AE that was considered by the investigator
to possibly be related to the study drug (vs 23.4% of pla-
cebo/PR-treated patients). A similar incidence of fatigue
was documented in the ASPIRE study: 43.9% of simepre-
vir/PR-treated patients experienced a fatigue AE (vs
43.9% of placebo/PR-treated patients) and 24.2% of these
patients had a fatigue AE that was considered to possibly
be related to the study drug (vs 22.7% of placebo/PR-
Table 1 Patient baseline demographic and disease characteristics for all treatment groups in PILLAR and ASPIRE
PILLAR ASPIRE
All simeprevir (N = 309) PR (N = 77) All simeprevir (N = 396) PR (N = 66)
Male, n (%) 174 (56.3) 39 (50.6) 269 (67.9) 42 (63.6)
Caucasian race, n (%) 288 (93.2) 74 (96.1) 366 (92.4) 62 (93.9)
Age (range), years† 47.0 (18–69) 45.0 (21–67) 50.0 (20–69) 50.5 (22–66)
Body mass index (range), kg/m2 † 24.9 (16.8–39.6) 25.6 (17.5–42.2) 27.0 (18.2–48.7) 28.0 (18.5–40.5)
HCV RNA (range) log10 IU/mL
† 6.6 (3.5–8.1) 6.6 (4.3–7.5) 6.6 (3.5–7.7) 6.6 (5.2–7.6)
HCV RNA >800,000 IU/mL, n (%) 268 (86.7) 63 (81.8) 344 (86.9) 55 (83.3)
HCV genotype, N‡ 307 76 389 66
1a, n (%) 144 (46.9) 29 (38.2) 161 (41.4) 27 (40.9)
1b, n (%) 161 (52.4) 47 (61.8) 223 (57.3) 39 (59.1)
Metavir score, N 309 77 391 64
F3, n (%) 46 (14.9) 7 (9.1) 73 (18.7) 13 (20.3)
F4, n (%) 1 (0.3) 0 (0) 73 (18.7) 10 (15.6)
EQ-5D, N 305 77 384 64
Baseline valuation index, mean (SE) 0.9 (0.01) 0.9 (0.03) 0.9 (0.01) 0.9 (0.02)
Baseline VAS, mean (SE) 82.2 (0.91) 83.6 (1.42)§ 80.3 (0.83) 80.5 (2.22)
FSS, N 195 50 385 64
Baseline, mean (SE) 3.3 (0.12) 3.2 (0.21) 3.4 (0.08) 3.2 (0.22)
†Median; ‡NS5B sequence-based assay; §n = 76.
PR placebo/peginterferon-α and ribavirin, HCV hepatitis C virus, EQ-5D European Quality of Life 5-Dimensions, SE standard error, FSS Fatigue Severity Scale,
VAS visual analog scale.
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treated patients). The incidence of Grade 3/4 fatigue
among simeprevir/PR-treated patients was <1.0% in both
studies (Grade 3/4 defined according to the World Health
Organization toxicity grading system as severe with marked
activity limitation, or potentially life-threatening with ex-
treme activity limitation).
FSS
A total of 245 (63.5%) patients in the PILLAR study and
449 (97.2%) patients in the ASPIRE study completed the
FSS during the baseline visit.a Mean baseline FSS scores in
the simeprevir/PR and placebo/PR groups were comparable
within and between studies (all simeprevir/PR groups: 3.31
[PILLAR], 3.37 [ASPIRE]; Table 2) and approximately 1
point higher than the established normative value for
FSS scores in healthy adults (mean ± standard error
[SE]: 2.3 ± 0.7) but roughly one point lower than pa-
tients with multiple sclerosis (MS) or systemic lupus
erythematosis (SLE) [26].
During the first 24 weeks of treatment, mean FSS total
scores were generally comparable and increased com-
pared with baseline among simeprevir/PR- and placebo/
PR-treated patients in both studies indicating a higher
degree of fatigue. After 24 weeks of treatment in the
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PR, placebo/peginterferon-α and ribavirin
SVR24, sustained virological response defined as hepatitis C virus RNA<25 IU/mL
Figure 2 Proportion of simeprevir/PR-treated patients achieving SVR24 in the PILLAR and ASPIRE studies.
Table 2 Mean change from baseline in FSS total scores at EOT and EOF
FSS total score PILLAR, n (%) ASPIRE, n (%)
All simeprevir (n = 309) PR (n = 77) All simeprevir (n = 396) PR (n = 66)
Week 24, N 174 (EOT)† 48 343 52
Mean change (±SE) 1.16 (0.120) 1.25 (0.237) 0.99 (0.080) 0.73 (0.217)
Week 36, N 172 45 346 53
Mean change (±SE) 0.06 (0.130) 1.08 (0.272) 0.91 (0.086) 0.43 (0.221)
Week 48, N 166 43 (EOT) 344 (EOT) 52 (EOT)
Mean change (±SE) −0.19 (0.132) 1.19 (0.267) 0.85 (0.085) 0.50 (0.220)
Week 60, N 164 43 342 54
Mean change (±SE) −0.49 (0.112) −0.15 (0.186) −0.05 (0.079) −0.03 (0.188)
Week 72, N 164 (EOF) 44 (EOF) 338 (EOF) 56 (EOF)
Mean change (±SE) −0.50 (0.108) −0.40 (0.219) −0.22 (0.079) −0.18 (0.202)
†For the majority of SMV-treated patients, EOT was 24 weeks; 55 patients in the SMV group continued PR therapy through to Week 48 as they did not meet the
response-guided therapy criteria at Week 24. FSS Fatigue Severity Scale, EOT end of treatment, EOF end of follow-up, PR placebo/peginterferon-α and ribavirin,
SE standard error.
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PILLAR study, an earlier decline in mean FSS total score
was observed in the simeprevir/PR group compared to
the placebo/PR group. Specifically, by Week 36 in the
PILLAR study (12 weeks after most patients [82.2%]
completed treatment), mean FSS total score had de-
creased to a value comparable to baseline (mean change
vs baseline 0.06) among the simeprevir/PR-treated pa-
tients and this decreased further to below the baseline
value at Week 48 and beyond (Table 2; Figure 3). In
comparison, in the PR group, improvement in FSS total
score to a value comparable to or below the baseline
value was not evident until Week 60. Figure 4 compares
change in total FSS score from baseline over time for
each treatment group stratified by duration of treatment
(≤192 days vs >192 days) for the PILLAR study. In the
simeprevir/PR treatment group, the best outcome in
terms of reduction in fatigue was achieved by those
patients who met RGT criteria and were able to
complete the optimum duration of simeprevir/PR therapy
(24 weeks).
In the ASPIRE study, improvement in fatigue compar-
able to baseline levels was reported at Week 60 in both
the simeprevir/PR and placebo/PR groups. The earlier
improvement in fatigue in the PILLAR study (Week 36)
compared with the ASPIRE study (Week 60) was consistent
with the implementation of RGT in PILLAR (but not
ASPIRE) allowing the PILLAR study patients to qualify
for shortened treatment duration and to discontinue
therapy at Week 24.
Statistical analyses of the PILLAR study using AUC
indicated significantly (P < 0.001) less fatigue over the
72-week treatment and follow-up period for patients
treated with simeprevir/PR (AUC = 250.2 [SE = 5.0])
than with placebo/PR (AUC = 283.9 [SE = 8.8]). In the
ASPIRE study, AUC indicated lower fatigue overall in
the placebo/PR group (AUC = 268.9 [SE = 9.4]) com-
pared to the simeprevir/PR group (AUC= 287.3 [SE = 5.1])
although this difference was not statistically significant.
Sensitivity analyses in both studies, including a LOCF
approach, and comparison of characteristics of patients
with and without baseline FSS data in the PILLAR study
(Table 3), indicated that the FSS results were unaffected
by missing data.
Correspondence of FSS self-reported fatigue severity
with fatigue AE data was comparable between the two
trials. The difference between the mean change from
baseline in FSS total scores for patients with fatigue AEs
compared with matched controls, who did not experi-
ence a fatigue AE, was 0.6 in the PILLAR study (mean
FSS change 1.1 vs 0.5 for controls; P = 0.011) and 0.5 in
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Figure 3 Change from baseline in FSS total score up to Week 72 for all simeprevir/PR treatment groups combined vs placebo/PR in
a) the PILLAR study and b) the ASPIRE study.
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the ASPIRE study (mean FSS change 0.9 vs 0.4 for con-
trols; P < 0.001).
EQ-5D descriptive system
At baseline, the proportion of patients reporting extreme
problems with their health status (most severe category)
in the simeprevir/PR and placebo/PR groups was low in
all dimensions (<4% of patients in any dimension, in
both studies). During both the PILLAR and ASPIRE
studies there were generally fewer problems in terms of
Mobility or Self-care. Pain, Mood Disturbances, and im-
pairment in Usual Activities were generally the most
common domains affected during treatment (Table 4).
In both trials, EQ-5D was only collected at baseline, Week
24, Week 48, and Week 72. In the treatment-naïve PILLAR
study population, the proportion of simeprevir/PR- and
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Figure 4 Mean change (±SE) from baseline in FSS total score up to Week 72 for all simeprevir/PR treatment groups combined vs
placebo/PR according to treatment duration in the PILLAR study.
Table 3 Baseline demographic and disease characteristics of patients in PILLAR with and without FSS scores at
baseline
With baseline FSS Without baseline FSS
All simeprevir (N = 195) PR (N = 50) All simeprevir (N = 114) PR (N = 27)
Male, n (%) 115 (59.0) 23 (46.0) 59 (51.8) 16 (59.3)
Caucasian race, n (%) 180 (92.3) 49 (98.0) 108 (94.7) 25 (92.6)
Age (range), years† 48.0 (18–69) 47.5 (21–61) 42.5 (18–66) 42.0 (21–67)
Body mass index (range), kg/m2† 25.1 (17.1–38.2) 25.7 (17.6–36.0) 24.7 (16.8–39.6) 25.6 (17.5–42.2)
HCV RNA (range) log10 IU/mL
† 6.6 (3.5–8.1) 6.6 (4.3–7.5) 6.5 (5.1–7.5) 6.2 (5.4–7.1)
HCV RNA >800,000 IU/mL, n (%) 170 (87.2) 43 (86.0) 98 (86.0) 20 (74.1)
HCV genotype, N‡
1a, n (%) 105 (53.8) 21 (42.0) 40 (35.1) 9 (33.3)
1b, n (%) 88 (45.1) 29 (58.0) 73 (64.0) 18 (66.7)
Metavir score, N
F3, n (%) 33 (16.9) 5 (10.0) 13 (11.4) 2 (7.4)
F4, n (%) 0 (0.0) 0 (0.0) 1 (0.9) 0 (0.0)
†Median; ‡NS5B sequence-based assay.
PR placebo/peginterferon-α and ribavirin, HCV hepatitis C virus, FSS Fatigue Severity Scale.
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placebo/PR-treated patients with problems relating to Usual
Activities, Pain, and Anxiety/Depression and to a lesser ex-
tent Mobility increased at Week 24 relative to baseline. By
Week 48 (24 weeks after most patients [82.2%] completed
treatment) in the simeprevir/PR groups, the number of pa-
tients with problems in these dimensions had decreased
compared with Week 24. A similar improvement (Week 48
vs Week 24) was evident in the placebo/PR group for the
Anxiety/Depression domain, although the proportion of pa-
tients with problems was higher than in the simeprevir/PR
group (Table 4).
Similar to the PILLAR study, problems in the Pain/
Discomfort, Usual Activities, Anxiety/Depression, and to
a lesser extent Mobility domains increased at Week 24
versus baseline among simeprevir/PR- and placebo/PR-
treated patients enrolled in the ASPIRE study. However,
in contrast, the ASPIRE patient population, who were all
prior HCV treatment-experienced patients (patients with
null or partial response or who relapsed), did not experi-
ence a reduction in health status problems (any dimen-
sion) at Week 48 versus Week 24; overall, health status
problems were generally similar across the simeprevir/
PR and placebo/PR treatment groups at these time-
points. By Week 72, the proportion of patients with
health status problems (any dimension) had returned to
levels similar to baseline in both studies.
EQ-5D valuation index
Mean EQ-5D valuation index values decreased compared
with baseline at Week 24 (indicating worsening of health
status) in the simeprevir/PR and placebo/PR groups in
both studies (PILLAR: −0.14, −0.13; ASPIRE: −0.13, −0.14,
respectively) with no relevant differences between treat-
ment groups (Figure 5). At Week 48 in the PILLAR study,
the mean EQ-5D valuation index was increased compared
with Week 24 in the simeprevir/PR group (mean change
from baseline: −0.03), indicating health status improve-
ment while in the placebo/PR group the mean decrease
from baseline remained relatively stable at Week 48 com-
pared with Week 24 (−0.11). The mean decrement in
utility during Weeks 0–48 was smaller among the
simeprevir/PR-treated patients (−0.067; 95% confidence
interval [CI]: −0.111, −0.024) compared with the placebo/
PR-treated patients (−0.119; 95% CI: −0.164, −0.075),
representing a difference of 0.052 (95% CI: −0.011, 0.114).
In contrast, no improvement in health status was ob-
served in the ASPIRE study at Week 48 in either the
simeprevir/PR or placebo/PR group (mean change
Table 4 Summary of patients reporting any health problem by EQ-5D domain in the PILLAR and ASPIRE studies
EQ-5D
domain
Study
visit
PILLAR, n/N (%) ASPIRE, n/N (%)
All simeprevir Placebo/PR All simeprevir Placebo/PR
Mobiity Baseline 21/306 (6.9) 5/77 (6.5) 27/386 (7.0) 6/64 (9.4)
Week 24 61/285 (21.5) 6/72 (8.3) 80/355 (22.6) 14/51 (27.5)
Week 48 25/271 (9.3) 11/67 (16.4) 76/352 (21.6) 11/55 (20.0)
Week 72 16/279 (5.7) 5/68 (7.4) 38/340 (11.2) 11/55 (20.0)
Self-care Baseline 3/306 (1.0) 2/77 (2.6) 5/387 (1.3) 2/64 (3.1)
Week 24 6/285 (2.1) 2/72 (2.8) 13/354 (3.7) 3/51 (5.9)
Week 48 5/271 (1.9) 2/68 (2.9) 18/352 (5.1) 5/55 (9.1)
Week 72 6/279 (2.2) 1/68 (1.5) 9/339 (2.7) 3/55 (5.5)
Usual activities Baseline 32/305 (10.5) 4/77 (5.2) 49/387 (12.6) 9/64 (14.1)
Week 24 148/284 (52.1) 36/72 (50.0) 159/354 (44.9) 18/51 (35.3)
Week 48 46/271 (17.0) 31/68 (45.5) 153/351 (43.6) 17/55 (30.9)
Week 72 36/279 (12.9) 8/68 (11.8) 55/338 (16.3) 12/55 (21.8)
Pain/discomfort Baseline 83/306 (27.1) 17/77 (22.1) 109/385 (28.3) 15/64 (23.4)
Week 24 154/285 (54.0) 45/72 (62.5) 193/354 (54.5) 21/51 (41.2)
Week 48 73/271 (27.0) 38/68 (55.9) 188/349 (53.9) 22/55 (40.0)
Week 72 64/279 (23.0) 19/68 (27.9) 107/337 (31.8) 21/55 (38.2)
Anxiety/ Baseline 71/306 (23.2) 15/77 (19.5) 80/385 (20.8) 11/64 (17.2)
depression Week 24 130/284 (45.7) 39/72 (54.2) 165/355 (46.4) 21/51 (41.2)
Week 48 65/271 (23.9) 24/68 (35.3) 168/351 (47.9) 20/55 (36.4)
Week 72 63/279 (22.6) 15/68 (22.0) 94/338 (27.9) 18/55 (32.7)
EQ-5D European Quality of Life 5-Dimensions, PR placebo/peginterferon-α and ribavirin.
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from baseline: −0.13, −0.13, respectively). The mean
decrement in utility during Weeks 0–48 was smaller
among the simeprevir/PR-treated patients (−0.135; 95%
CI: −0.187, −0.082) than among placebo/PR-treated
patients (−0.155; 95% CI: −0.215, −0.095) representing a
difference of 0.02024 (−0.0598 to 0.10028). By Week 72,
mean EQ-5D valuation index values had increased to
values similar to those reported at baseline in both the
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Figure 5 Mean change from baseline in a) EQ-5D valuation index values and b) EQ-5D VAS for all simeprevir/PR treatment groups
combined vs placebo/PR in the PILLAR and ASPIRE studies.
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simeprevir/PR and placebo/PR treatment groups in both
studies (Figure 5).
EQ-5D VAS
After 24 weeks of treatment in the PILLAR and ASPIRE
studies, both simeprevir/PR- and placebo/PR-treated pa-
tients rated their health status as having significantly
worsened, as denoted by a decrease in mean VAS values
compared with baseline of more than 10 points (PIL-
LAR: −13.3, −16.0; ASPIRE: −11.0, −10.5, respectively)
(Figure 5). In the PILLAR study, mean VAS returned to
values similar to baseline by Week 48 (mean VAS change
0.12) and was improved versus baseline by Week 72 (2.26)
in the simeprevir/PR group. In the ASPIRE study mean
VAS values were worse versus baseline at Week 48 but
had improved versus baseline by Week 72 (mean VAS
change −9.7 and 2.1, respectively).
Mean EQ-5D VAS scores in the simeprevir/PR group
remained lower at Week 24 and 48 than in the placebo/
PR group in the ASPIRE study. This is likely a reflection
that more patients in the simeprevir/PR group continued
on treatment with PR through Week 48 while the pla-
cebo/PR-treated patients were more likely to discontinue
treatment by Week 20 due to meeting a virology stop-
ping rule that indicated treatment failure. In the pla-
cebo/PR groups, mean EQ-5D VAS did not return to
values similar to baseline until Week 72 in either
study.
Sensitivity analyses in each study, including a LOCF
approach, and comparison of patients with and without
baseline FSS scores in the PILLAR study (Figure 6)
indicated that the EQ-5D VAS results were unaffected
by missing data.
Discussion
In the current analysis we evaluated patient-reported fatigue
and health status associated with the addition of sime-
previr to PegIFN/RBV in treatment-naïve and treatment-
experienced patients with HCV genotype 1 infection.
Fatigue is the most common symptom reported by in-
dividuals infected with HCV and is one of the most
common treatment-related AEs among those who undergo
treatment [16-18]. Increased fatigue is associated with re-
ductions in HRQoL during treatment. The findings in both
treatment-naïve and treatment-experienced patients indi-
cate that the addition of simeprevir to PegIFN/RBV does
not worsen fatigue and other health-related outcomes,
above that already observed with PegIFN/RBV alone. As
expected in both the PILLAR and ASPIRE studies, fatigue
and other health-related dimensions initially worsened dur-
ing therapy in all treatment groups (simeprevir/PR and pla-
cebo/PR); however, during the second part of treatment
(Week 24 and beyond) fatigue severity and health status
tended to stabilize and did not worsen further. Among the
EQ-5D health dimensions assessed, Usual Activities, Pain
Discomfort, and Anxiety/Depression all initially worsened
during HCV therapy whilst Mobility and, to a greater ex-
tent, Self-Care remained primarily unaffected by treatment.
A lower on-treatment disutility observed in the simeprevir/
PR group compared with the placebo/PR group indicates
less time with worse health status versus baseline in the
simeprevir/PR group.
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In the PILLAR study, the shorter PR treatment dur-
ation and higher SVR rates in the simeprevir/PR groups
enabled simeprevir/PR-treated patients to experience
less time with fatigue and lower health functioning com-
pared with placebo/PR-treated patients. Of particular
note was the fact that the majority (82.2%) of treatment-
naïve patients treated with simeprevir/PR in the PILLAR
study stopped all therapy at Week 24 according to the
criteria for RGT; termination of therapy at Week 24 was
subsequently followed by improvements in FSS and
EQ-5D scores by the next available timepoint, denoting
a reduction in fatigue and improvement in health status,
among simeprevir/PR-treated patients. For the small
number of simeprevir/PR patients who achieved insuffi-
cient viral response to meet RGT (n = 15) and received a
longer duration of PR therapy (>192 days) higher fatigue
scores were reported up to Week 48. In addition, fatigue
scores were also higher up to Week 48 for patients in
the placebo/PR group who were able to remain on treat-
ment through to this time point (i.e. did not discontinue
placebo/PR therapy early due to AEs or lack of viral re-
sponse). These findings underscore the benefit, in terms
of patient-reported fatigue and perceived health status,
of a shorter overall duration of treatment for chronic
HCV infection, which can be realized for the majority of
patients treated with simeprevir/PR through the imple-
mentation of RGT.
In ASPIRE, where patients had previously failed to
sustain a viral response following treatment with inter-
feron, treatment with PR was scheduled to last until
Week 48 for all patients. However, patients in the pla-
cebo/PR group were more likely to discontinue all treat-
ment by Week 20 because they were unable to achieve
adequate virologic response to treatment. The shorter
duration of PR treatment in the placebo/PR group
coupled with no RGT permitted for the simeprevir/PR-
treated patients led to better HRQoL (higher EQ-VD
VAS scores) at Weeks 24 and 48 in the placebo/PR
group compared to the simeprevir/PR group. Focusing on
this temporary advantage in HRQoL in the placebo/PR
group at Weeks 24 and 48 ignores the long-term HRQoL
consequences of persistent HCV infection for these pa-
tients who failed to achieve SVR with PR treatment alone.
Patient-reported fatigue data provide an important
addition to fatigue-related AE data documented during
the course of a clinical trial. The incidence and severity
of fatigue AEs were comparable in all treatment groups
in both studies (42.4−48.1% of patients). However, pa-
tient reports enrich our understanding of the fatigue ex-
perienced by patients in each study. Adding simeprevir
to PR did not increase the severity of fatigue in either
study; however, when virologic response was used to
guide the duration of PR therapy (PILLAR only), the
duration of treatment-related increases in fatigue was
significantly reduced. Used in conjunction with AE data,
patient-reported data could be used to aid discussion be-
tween patients and clinicians regarding what to expect
from treatment and may ultimately help to inform treat-
ment decisions in the HCV treatment setting. Specific-
ally, the data could enable clinicians to advise patients
on how long they are likely to experience fatigue and
which aspects of daily functioning are most likely to be
affected and when. For example, our data suggest that
patients are more likely to experience worsening of usual
activities, pain and discomfort, and mood-related symp-
toms compared with mobility or inability to provide self-
care during HCV therapy, and that these effects are
likely to occur for as long as they are on PR therapy.
Given the high incidence of fatigue among HCV-
infected patients treated with antiviral therapy there is a
need for a short, simple, reliable, and valid instrument to
assess fatigue in HCV and inform treatment decisions.
The findings from a recent validation study suggest that
the FSS offers a reliable assessment of self-reported fa-
tigue among patients with chronic HCV infection [25].
An FSS score of 2.3 is the recommended normal refer-
ence value for general population fatigue levels [28]. In
both the PILLAR and ASPIRE studies, the FSS mean
scores at baseline for HCV-infected patients were in ex-
cess of 3.0 which suggests many patients had clinically
important fatigue prior to initiating treatment. By com-
parison, mean FSS scores indicating severe fatigue have
been reported using the FSS in patients with MS (4.66)
and SLE (4.7) [26]. Given FSS scores in all treatment
groups in both studies increased to levels similar to
those reported by patients with MS or SLE while pa-
tients were taking PR, there is clear evidence that short-
ening the duration of fatigue associated with HCV
treatment is a significant clinical benefit for patients.
The blinded analyses from PILLAR and ASPIRE link-
ing fatigue AEs to FSS scores also support the validity of
the FSS as a measure of fatigue in HCV and indicate that
mean changes in FSS scores as small as 0.5 are clinically
important for patients with chronic HCV infection. A
recent validation of the FSS based on data from PILLAR
and ASPIRE also concluded that an interpretable and
meaningful improvement in fatigue occurs when there is
an observed-group mean change in FSS total score of
between 0.33 and 0.82 [25]. Phase III simeprevir studies
using the FSS evaluated response to treatment using
these criteria and found shorter duration of worsening
in fatigue associated with simeprevir/PR treatment than
with placebo/PR in treatment-naïve patients and in pa-
tients who relapsed following PR treatment [36]. How-
ever, as the response criteria were created based on the
PILLAR and ASPIRE data, a responder analysis was not
pre-specified or conducted for the Phase IIb PILLAR
and ASPIRE trials.
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The current analysis was subject to some study limita-
tions. In the PILLAR study, patients completed an FSS
with a 14-day (2-week) recall while patients in the
ASPIRE study completed the FSS using a 7-day (1-week)
recall of symptoms and functioning problems. It is not
possible to identify how much the difference in recall
period may have affected FSS scores in this study. How-
ever, the chronicity of fatigue in this population and the
close association between fatigue scores and PR treatment
observed in this and other trials [36] suggests that the re-
call made little difference in this chronically ill patient
population who were on fatigue-inducing treatments for
many weeks.
In both the PILLAR and ASPIRE studies, patients and
clinicians were blinded to the laboratory HCV RNA re-
sults and to why treatment was stopped prior to Week 48.
Treatment could be stopped for several reasons: due to
treatment failure (lack of response), severe AEs, or in PIL-
LAR due to virologic response at Weeks 4 and 12. Sensi-
tivity analyses compared FSS scores for patients treated
with simeprevir/PR who had 192 days of treatment or less
with those who completed more than 192 days of treat-
ment (24 weeks) to evaluate the impact of RGT on FSS
scores. Regardless of why patients discontinued treatment
(because of meeting a stopping rule, meeting RGT
criteria, or completing 48 weeks of treatment), the
patient-reported outcome data were consistent with
these problems being determined primarily by duration
of PegIFN/RBV treatment.
It is important to recognize that patients in both the
PILLAR and ASPIRE studies were blinded to simeprevir
treatment assignment; however, PR treatment could not
be blinded when treatment was stopped, although the
reason for stopping was not disclosed. The strong associ-
ation seen between duration of PR and patient-reported
outcomes may be, in part, due to the inability to blind
subjects to PR treatment duration.
This study was also limited by the fact that approxi-
mately 40% of patients in the PILLAR study did not have
baseline FSS data either because translations of the FSS
questionnaire in the patients’ native language were not
available when the first study sites began patient enrol-
ment or because of an error in the response scale for the
FSS completed by the patients who initially entered the
trial. Post hoc comparisons of patient demographics, dis-
ease characteristics at baseline, and EQ-5D VAS over the
course of the study for patients with and without FSS at
baseline indicated no major differences between the pa-
tients without baseline FSS and those patients included
in the FSS analysis (Table 3, Figure 6). These sensitivity
analyses found no evidence to suggest that the missing
FSS data biased the results.
Both studies used procedures consistent with recom-
mended practice to reduce missing data in patient
questionnaires completed during clinical trials. The re-
quirement that staff check each questionnaire a patient
completed and ask that all questions be answered may
have introduced bias in these results that cannot be
evaluated here. Future studies that ask patients to
complete questionnaires on computerized devices that
can remind patients to answer any skipped questions
will help eliminate any bias that may be introduced by
asking staff to check for missing data that are required
for paper- and pencil-administration.
Conclusions
Patients in the PILLAR and ASPIRE trials with chronic
HCV infection treated with simeprevir in combination
with PR experience a similar safety/tolerability profile
and a higher SVR rate compared with patients treated
with PR alone. For treatment-naïve patients in the PIL-
LAR study, high SVR rates were achieved even though
most patients who received simeprevir were able to limit
PR treatment to only 24 weeks because they met RGT
criteria. The clinical benefits associated with the addition
of simeprevir arise without a significant increase in
patient-reported fatigue beyond that reported in patients
treated with PR alone, and for many patients is associ-
ated with shorter duration of health impairment (fatigue
and health status) compared with PR.
Endnote
aThe PILLAR study was the first simeprevir trial to in-
clude patient-reported outcome endpoints. Sites that en-
rolled the first patients did not have appropriate language
translations of the patient-reported outcome instruments
for their subjects to complete at their baseline visit. Some
of these patients subsequently completed patient-reported
outcome instruments at post-baseline visits but data from
these patients were not included in the treatment compar-
isons due to lack of baseline data.
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